Table 3.
Characteristic Differences and Endpoint Distributions Among 17,171 Antiretroviral Therapy Initiators in the North American AIDS Cohort Collaboration on Research and Design, By Black Race, 2000–2010
| Characteristica | Black | Nonblack | p |
|---|---|---|---|
| Total | 7565 (44) | 9606 (56) | |
| Time in follow-up (years) | 3.82 (1.8, 6.0) | 4.08 (1.9, 6.3) | <0.001 |
| Age (years) | 47 (40, 55) | 47 (39, 55) | 0.62 |
| Sex | <0.001 | ||
| Male | 5815 (40) | 8556 (60) | |
| Female | 1750 (62) | 1050 (38) | |
| HIV risk | <0.001 | ||
| Non-IDU | 5731 (41) | 8228 (59) | |
| IDU | 1834 (57) | 1378 (43) | |
| CD4+ countb (cells/mm3) | 231 (66, 404) | 270 (103, 456) | <0.001 |
| Nadir CD4+ countc (cells/mm3) | 144 (30, 272) | 176 (57, 302) | <0.001 |
| HIV-1 RNAd (log10 copies/mL) | 4.521 (3.42, 5.13) | 4.531 (3.21, 5.17) | 0.99 |
| Event | N | Years in FU | N | Years in FU | p |
|---|---|---|---|---|---|
| Death | 738 | 2.66 (1.51, 4.32) | 773 | 2.88 (1.51, 4.82) | 0.17 |
| Discontinuity in care | 3830 | 2.41 (1.42, 4.19) | 4537 | 2.46 (1.40, 4.22) | 0.75 |
| Event free | 2997 | 5.79 (4.23, 7.88) | 4296 | 5.85 (4.26, 7.92) | 0.77 |
p-Value calculated by χ2 for categorical variables, Kruskal–Wallis for continuous variables.
a
Numbers presented as N (%) if categorical, as median (IQR) if continuous.
b
At ART initiation, available for N = 14,356 individuals.
c
After ART initiation, available for N = 17,171 individuals.
d
At ART initiation, available for N = 14,261 individuals.
ART, antiretroviral therapy; FU, follow-up; IDU, injection drug use; IQR, interquartile range.